Zions Bancorporation National Association UT Buys 3,447 Shares of Haemonetics Corporation $HAE

Zions Bancorporation National Association UT grew its stake in shares of Haemonetics Corporation (NYSE:HAE) by 8.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,621 shares of the medical instruments supplier’s stock after purchasing an additional 3,447 shares during the quarter. Zions Bancorporation National Association UT owned approximately 0.10% of Haemonetics worth $3,478,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Citigroup Inc. raised its holdings in Haemonetics by 87.3% during the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after buying an additional 291,574 shares during the last quarter. MetLife Investment Management LLC grew its holdings in Haemonetics by 448.0% in the 1st quarter. MetLife Investment Management LLC now owns 316,542 shares of the medical instruments supplier’s stock worth $20,116,000 after acquiring an additional 258,776 shares during the last quarter. Nuveen LLC purchased a new position in shares of Haemonetics in the first quarter valued at about $10,340,000. AQR Capital Management LLC raised its stake in shares of Haemonetics by 591.6% during the first quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after acquiring an additional 149,325 shares during the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Haemonetics by 60.6% during the first quarter. Raymond James Financial Inc. now owns 390,856 shares of the medical instruments supplier’s stock valued at $24,839,000 after acquiring an additional 147,492 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Citigroup cut their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Mizuho decreased their target price on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and dropped their price target for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. Finally, BTIG Research lifted their price target on shares of Haemonetics from $85.00 to $88.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $78.50.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $68.70 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $3.31 billion, a P/E ratio of 21.01, a P/E/G ratio of 0.91 and a beta of 0.43. The business has a fifty day simple moving average of $51.53 and a two-hundred day simple moving average of $62.12. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.